CDEK
← All drugs Report issue

tg-100801

Small moleculeexperimental

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2006 (NCT00414999)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Mol. weight
580.09 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol
  • tg100801
  • tg100801
  • tg100801
  • tg 100801
  • tg-100801
  • tg-100801
  • tg100-801
  • tg100-801

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00509548Phase 2Jul 1, 2007TargeGen, University of Rochester
NCT00414999Phase 1Nov 1, 2006IQVIA, TargeGen
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TargeGenFor profit2222006
IQVIAFor profit1012006
University of RochesterAcademic/Hospital1012007
3 organizations
Page 1 / 1